Immunologic treatment of Parkinson's disease

References

• 1 Obeso JA, Stamelou M, Goetz CG et al. Past, present, and future of Parkinson's disease: a special essay on the 200th Anniversary of the Shaking Palsy. Mov. Disord. 32(9), 1264–1310 (2017).
  Medline CASGoogle Scholar
• 2 Rousseaux M, Shulman J, Jankovic J. Progress toward an integrated understanding of Parkinson's disease. F1000 Research. 6, 1121 (2017).
  MedlineGoogle Scholar
• 3 Lotia M, Jankovic J. New and emerging medical therapies in Parkinson's disease. Exp. Opin. Pharmacother. 17(7), 895–909 (2016).
  Medline CASGoogle Scholar
• 4 Tarakad A, Jankovic J. Diagnosis and management of Parkinson's disease. Semin. Neurol. 37(2), 118–126 (2017).
  MedlineGoogle Scholar
• 5 Kannoth S, Anandakkuttan A, Mathai A, Sasikumar AN, Nambiar V. Autoimmune atypical parkinsonism – a group of treatable parkinsonism. J. Neurol. Sci. 15(362), 40–6 (2016).
  Google Scholar
• 6 Baizabal-Carvallo JF, Jankovic J. Movement disorders in autoimmune diseases. Mov. Disord. 27(8), 935–946 (2012).
  Medline CASGoogle Scholar
• 7 Parashar A, Udayabanu M. Gut microbiota: implications in Parkinson's disease. Parkinsonism Relat. Disord. 38, 1–7 (2017).
  MedlineGoogle Scholar
• 8 Marizzoni M, Provasi S, Cattaneo A, Frisoni GB. Microbiota and neurodegenerative diseases. Curr. Opin. Neurol. (Epub ahead of print), (2017).
  MedlineGoogle Scholar
• 9 Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJ, Kraneveld AD. Exploring Braak's hypothesis of Parkinson's disease. Front. Neurol. 13(8), 37 (2017).
  Google Scholar
• 10 Sampson TR, Debelius JW, Thron T et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 167(6), 1469–1480.e12 (2016).
  Medline CASGoogle Scholar
• 11 Aono H, Choudhury ME, Higaki H et al. Microglia may compensate for dopaminergic neuron loss in experimental Parkinsonism through selective elimination of glutamatergic synapses from the subthalamic nucleus. Glia 65(11), 1833–1847 (2017).
  MedlineGoogle Scholar
• 12 Blaylock RL. Parkinson's disease: microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegeneration. Surg. Neurol. Int. 26(8), 65 (2017).
  Google Scholar
• 13 Dhillon JS, Riffe C, Moore BD et al. A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies. PLoS One 12(9), e0184731 (2017).
  MedlineGoogle Scholar
• 14 Sulzer D, Alcalay RN, Garretti F et al. T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature 546(7660), 656–661 (2017).
  Medline CASGoogle Scholar
• 15 Holmans P, Moskvina V, Jones L et al. A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Hum. Mol. Genet. 22(5), 1039–1049 (2013).
  Medline CASGoogle Scholar
• 16 Witoelar A, Jansen IE, Wang Y et al. Genome-wide pleiotropy between Parkinson disease and autoimmune diseases. JAMA Neurol. 74(7), 780–792 (2017).
  MedlineGoogle Scholar
• 17 Lawand NB, Saadé NE, El-Agnaf OM, Safieh-Garabedian B. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease. Expert Opin. Ther. Targets 19(10), 1351–1360 (2015).
  Medline CASGoogle Scholar
• 18 Dehay B, Bourdenx M, Gorry P et al. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol. 14(8), 855–66 (2015).
  Medline CASGoogle Scholar
• 19 Dehay B, Decressac M, Bourdenx M et al. Targeting alpha-synuclein: therapeutic options. Movement Dis. 31(6), 882–888 (2016).
  Medline CASGoogle Scholar
• 20 Games D, Valera E, Spencer B et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J. Neurosci. 34(28), 9441–9454 (2014).
  MedlineGoogle Scholar
• 21 Sahin C, Lorenzen N, Lemminger L et al. Antibodies against the C-terminus of α-synuclein modulate its fibrillation. Biophys. Chem. 220, 34–41 (2017).
  Medline CASGoogle Scholar
• 22 Spencer B, Valera E, Rockenstein E et al. Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy. Acta. Neuropathol. Commun. 5(1), 7 (2017).
  MedlineGoogle Scholar
• 23 Schenk DB, Koller M, Ness DK et al. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. Mov. Disord. 32(2), 211–218 (2017).
  Medline CASGoogle Scholar
• 24 Jankovic J, Goodman I, Safirestein B et al. Results from a phase 1b multiple ascending-dose study of PRX002, an anti–alpha-synuclein monoclonal antibody, in patients with Parkinson's disease. Neurodegener. Dis. (Suppl. 1), 567 (2017).
  Google Scholar
• 25 Weihofen A, Patel H, Huy C et al. Binding and functional characterization of human-derived anti-alpha-synuclein antibody BIIB054. Neurodegener. Dis. (Suppl. 1), 590 (2017).
  Google Scholar
• 26 Mandler M, Valera E, Rockenstein E et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta. Neuropathol. 127(6), 861–79 (2014).
  Medline CASGoogle Scholar
• 27 Mandler M, Valera E, Rockenstein E et al. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol. Neurodegener. 19(10), 10 (2015).
  Google Scholar
• 28 Wu Y, Le W, Jankovic J. Preclinical biomarkers of Parkinson disease. Arch. Neurol. 68(1), 22–30 (2011).
  MedlineGoogle Scholar